Digemid Withdraws Immunosuppressant Drug Batch Azathioprine Due to Health Risk

La República reports that Peru's health authority, Digemid, has taken decisive action by ordering the withdrawal of a specific batch of the immunosuppressant drug azathioprine. This move, prompted by a critical quality control failure, highlights the vigilance of Peruvian health regulators in safeguarding public well-being. The affected batch, identified as 25GT0891 of AZAGLOB 50 mg, failed to meet standards for azathioprine content, raising concerns about its efficacy and safety for patients. Azathioprine is a vital medication for individuals who have undergone organ transplants and for those managing serious autoimmune conditions like lupus and hepatitis. The potential for under-dosing or inconsistent dosage poses a significant risk to these vulnerable patient populations. Digemid's swift action, including the order for destruction of the compromised batch, underscores its commitment to maintaining high pharmaceutical standards. The report also serves as a crucial public health announcement, urging consumers to check their medication and report any concerns, reinforcing the collaborative effort needed between regulatory bodies and the public to ensure medication safety in Peru.

“

The azathioprine is an immunosuppressant medication used to prevent organ transplant rejection and treat autoimmune diseases such as lupus, arthritis, and autoimmune hepatitis, so an alteration in its composition could affect the effectiveness of the treatment.